Viridian Therapeutics Inc VRDN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VRDN is a good fit for your portfolio.
News
-
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
VIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm
-
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
-
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
Trading Information
- Previous Close Price
- $14.90
- Day Range
- $13.50–14.34
- 52-Week Range
- $10.93–28.35
- Bid/Ask
- $13.00 / $13.50
- Market Cap
- $887.77 Mil
- Volume/Avg
- 1.7 Mil / 899,865
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2,123.72
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 94
Comparables
Valuation
Metric
|
VRDN
|
CBAY
|
CELC
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.42 | 12.65 | 3.21 |
Price/Sales | 2,123.72 | 111.01 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
VRDN
CBAY
CELC
Financial Strength
Metric
|
VRDN
|
CBAY
|
CELC
|
---|---|---|---|
Quick Ratio | 17.93 | 10.70 | 12.78 |
Current Ratio | 18.26 | 10.96 | 13.43 |
Interest Coverage | −137.76 | −5.27 | −12.43 |
Quick Ratio
VRDN
CBAY
CELC
Profitability
Metric
|
VRDN
|
CBAY
|
CELC
|
---|---|---|---|
Return on Assets (Normalized) | −42.76% | −30.06% | −34.93% |
Return on Equity (Normalized) | −82.42% | −51.97% | −48.20% |
Return on Invested Capital (Normalized) | −50.70% | −30.87% | −38.54% |
Return on Assets
VRDN
CBAY
CELC
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ghlsmxfk | Fdp | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ykmhjkhp | Wqkds | $105.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Btqkqrvq | Pwschg | $105.3 Bil | |
MRNA
| Moderna Inc | Bbcsmgrl | Ppwtw | $46.7 Bil | |
ARGX
| argenx SE ADR | Jgrckgjt | Bsxb | $23.5 Bil | |
BNTX
| BioNTech SE ADR | Sttvtkjwb | Bvgyd | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Shhgkztvc | Rpchdc | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qwszdvhfx | Ydgzjf | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hllllxrfc | Pmxpwnx | $12.6 Bil | |
INCY
| Incyte Corp | Xhsmfbl | Hglvq | $12.0 Bil |